Tags

Type your tag names separated by a space and hit enter

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients.
Sci Immunol. 2020 10 08; 5(52)SI

Abstract

We measured plasma and/or serum antibody responses to the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2 in 343 North American patients infected with SARS-CoV-2 (of which 93% required hospitalization) up to 122 days after symptom onset and compared them to responses in 1548 individuals whose blood samples were obtained prior to the pandemic. After setting seropositivity thresholds for perfect specificity (100%), we estimated sensitivities of 95% for IgG, 90% for IgA, and 81% for IgM for detecting infected individuals between 15 and 28 days after symptom onset. While the median time to seroconversion was nearly 12 days across all three isotypes tested, IgA and IgM antibodies against RBD were short-lived with median times to seroreversion of 71 and 49 days after symptom onset. In contrast, anti-RBD IgG responses decayed slowly through 90 days with only 3 seropositive individuals seroreverting within this time period. IgG antibodies to SARS-CoV-2 RBD were strongly correlated with anti-S neutralizing antibody titers, which demonstrated little to no decrease over 75 days since symptom onset. We observed no cross-reactivity of the SARS-CoV-2 RBD-targeted antibodies with other widely circulating coronaviruses (HKU1, 229 E, OC43, NL63). These data suggest that RBD-targeted antibodies are excellent markers of previous and recent infection, that differential isotype measurements can help distinguish between recent and older infections, and that IgG responses persist over the first few months after infection and are highly correlated with neutralizing antibodies.

Authors+Show Affiliations

Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA. Department of Medicine, Harvard Medical School, Boston, MA, USA.Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA. Department of Medicine, Harvard Medical School, Boston, MA, USA. Department of Microbiology, Harvard Medical School, Boston, MA, USA.Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA. Department of Medicine, Harvard Medical School, Boston, MA, USA. Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA. Department of Medicine, Harvard Medical School, Boston, MA, USA.Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA. Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA. Department of Microbiology, Harvard Medical School, Boston, MA, USA.Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA. Department of Medicine, Harvard Medical School, Boston, MA, USA. Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA.Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA. Department of Pediatrics, Harvard Medical School, Boston, MA, USA.Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA. rcharles@mgh.harvard.edu. Department of Medicine, Harvard Medical School, Boston, MA, USA.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

33033172

Citation

Iyer, Anita S., et al. "Persistence and Decay of Human Antibody Responses to the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 Patients." Science Immunology, vol. 5, no. 52, 2020.
Iyer AS, Jones FK, Nodoushani A, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020;5(52).
Iyer, A. S., Jones, F. K., Nodoushani, A., Kelly, M., Becker, M., Slater, D., Mills, R., Teng, E., Kamruzzaman, M., Garcia-Beltran, W. F., Astudillo, M., Yang, D., Miller, T. E., Oliver, E., Fischinger, S., Atyeo, C., Iafrate, A. J., Calderwood, S. B., Lauer, S. A., ... Charles, R. C. (2020). Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Science Immunology, 5(52). https://doi.org/10.1126/sciimmunol.abe0367
Iyer AS, et al. Persistence and Decay of Human Antibody Responses to the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 Patients. Sci Immunol. 2020 10 8;5(52) PubMed PMID: 33033172.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. AU - Iyer,Anita S, AU - Jones,Forrest K, AU - Nodoushani,Ariana, AU - Kelly,Meagan, AU - Becker,Margaret, AU - Slater,Damien, AU - Mills,Rachel, AU - Teng,Erica, AU - Kamruzzaman,Mohammad, AU - Garcia-Beltran,Wilfredo F, AU - Astudillo,Michael, AU - Yang,Diane, AU - Miller,Tyler E, AU - Oliver,Elizabeth, AU - Fischinger,Stephanie, AU - Atyeo,Caroline, AU - Iafrate,A John, AU - Calderwood,Stephen B, AU - Lauer,Stephen A, AU - Yu,Jingyou, AU - Li,Zhenfeng, AU - Feldman,Jared, AU - Hauser,Blake M, AU - Caradonna,Timothy M, AU - Branda,John A, AU - Turbett,Sarah E, AU - LaRocque,Regina C, AU - Mellon,Guillaume, AU - Barouch,Dan H, AU - Schmidt,Aaron G, AU - Azman,Andrew S, AU - Alter,Galit, AU - Ryan,Edward T, AU - Harris,Jason B, AU - Charles,Richelle C, PY - 2020/07/28/received PY - 2020/10/05/accepted PY - 2020/10/9/entrez PY - 2020/10/10/pubmed PY - 2020/10/28/medline JF - Science immunology JO - Sci Immunol VL - 5 IS - 52 N2 - We measured plasma and/or serum antibody responses to the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2 in 343 North American patients infected with SARS-CoV-2 (of which 93% required hospitalization) up to 122 days after symptom onset and compared them to responses in 1548 individuals whose blood samples were obtained prior to the pandemic. After setting seropositivity thresholds for perfect specificity (100%), we estimated sensitivities of 95% for IgG, 90% for IgA, and 81% for IgM for detecting infected individuals between 15 and 28 days after symptom onset. While the median time to seroconversion was nearly 12 days across all three isotypes tested, IgA and IgM antibodies against RBD were short-lived with median times to seroreversion of 71 and 49 days after symptom onset. In contrast, anti-RBD IgG responses decayed slowly through 90 days with only 3 seropositive individuals seroreverting within this time period. IgG antibodies to SARS-CoV-2 RBD were strongly correlated with anti-S neutralizing antibody titers, which demonstrated little to no decrease over 75 days since symptom onset. We observed no cross-reactivity of the SARS-CoV-2 RBD-targeted antibodies with other widely circulating coronaviruses (HKU1, 229 E, OC43, NL63). These data suggest that RBD-targeted antibodies are excellent markers of previous and recent infection, that differential isotype measurements can help distinguish between recent and older infections, and that IgG responses persist over the first few months after infection and are highly correlated with neutralizing antibodies. SN - 2470-9468 UR - https://www.unboundmedicine.com/medline/citation/33033172/Persistence_and_decay_of_human_antibody_responses_to_the_receptor_binding_domain_of_SARS_CoV_2_spike_protein_in_COVID_19_patients_ L2 - https://immunology.sciencemag.org/cgi/pmidlookup?view=long&pmid=33033172 DB - PRIME DP - Unbound Medicine ER -